StreetAlpha.app
Home › Stocks › REPL

Replimune Group, Inc. (REPL)

Healthcare
$19.69
▼ −8.03%
LAST CLOSE · NOV 17

Replimune develops oncolytic immunotherapies, treatments built on engineered viruses that target skin cancers. It last closed at $19.69 on Nov 17, down 8.03% on the day. REPL reports earnings on Tue, Feb 2, 2027. The average 12-month price target from 4 analysts is $24.00 (+21.9% from the last close), with a high of $31.00 and a low of $17.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 4 dark pool prints totaling $5.2M, the largest $1.5M.

AI Auto Pilots
Is REPL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$271.0M
EPS (diluted)
−$2.79
Free cash flow
−$245.8M
Valuation
Market cap
$1.9B
94.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$307.8M
At Sep 30
Debt
$99.8M
At Sep 30
Shareholder equity
$204.8M
Shares outstanding
94.8M
At Oct 23
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: −$118.0M−$118.0MFY2022FY2023: −$174.3M−$174.3MFY2023FY2024: −$215.8M−$215.8MFY2024FY2025: −$247.3M−$247.3MFY2025FY2026: −$313.9M−$313.9MFY2026

From REPL's SEC filings, latest 10-Q/A for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 2
2027 · Time not announced
Consensus EPS forecast
-$0.57
$11.0M revenue est.
Year-ago EPS
-$0.77
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on REPL in the past 90 days
Average 12-month target
$24.00
▲ 21.9% upside

Based on 4 analysts who set a price target on REPL in the past 90 days. The average target is $24.00, with a high of $31.00 and a low of $17.00, compared with the last close of $19.69.

$3$13$23$33PAST 38 TRADING DAYS12-MONTH TARGETSHIGH $31AVG $24LOW $17May 29LAST CLOSE+12 MO$3$13$23$33PAST 38 DAYSTARGETSHIGH $31AVG $24LOW $17May 29LAST CLOSE+12 MO
Highest target$31.00
Average target$24.00
Lowest target$17.00
Latest rating changes
Piper SandlerMaintained
Nov 16Buy$27
Leerink PartnersTarget raised
Oct 29Buy$17 → $31
Roth MKMInitiated
Sep 25Buy$17
JP MorganTarget raised
Aug 26Buy$20 → $21
JP MorganMaintained
Aug 7Buy$20
DateFirmActionRatingPrice target
Nov 16Piper SandlerMaintainedBuy$27
Oct 29Leerink PartnersTarget raisedBuy$17 → $31
Sep 25Roth MKMInitiatedBuy$17
Aug 26JP MorganTarget raisedBuy$20 → $21
Aug 7JP MorganMaintainedBuy$20
Loading…

Technical Analysis

REPL · as of the Nov 17 close · updated after every close
Uptrend

The stock is 7% above its 20 day and 24% above its 50 day average. It is 49% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $19.01, and the nearest resistance the Pivot at $20.28.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 6.8%/day
Key levels
$23.4152 week high+18.9%
$23.41Swing high (Nov 10)+18.9%
$20.96Pivot R1+6.4%
$20.28Pivot+3.0%
$19.69Last close
$19.01Pivot S1−3.5%
$18.3320 day average−6.9%
$14.9950 day average−23.9%
$14.90Swing low (Aug 31)−24.3%
$13.65100 day average−30.7%
$10.13200 day average−48.6%
$1.5052 week low−92.4%
Indicators
RSI (14)58.00Middle of its rangeNeutral
MACD2.17Above its signal lineBullish
Stochastic72.2Middle of its rangeNeutral
ADX (14)41.2Strong uptrend
Williams %R-51.6Oversold below −80, overbought above −20Neutral
CCI (20)39.4Oversold below −100, overbought above 100Neutral
Rate of change−4.7%Change over 10 sessionsBearish
ATR (14)$1.33Typical daily range, 6.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for REPL

What happened before

See how REPL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow REPL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How REPL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in REPL in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$5.2M
Largest print
$1.5M
Loading…

REPL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●115 buying vs 104 selling
  • ▲Held by funds +11.3 pts
  • ▲Funds holding +6
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding209203+3.0%
In funds' top 10330.0%
Held by funds112.1%100.8%+11.3 pts
New / increased48 / 6775 / 72−21.8%
Reduced / sold out62 / 4244 / 54+6.1%
Put/call ratio0.050.33−85.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See REPL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REPL is in one of them and how their past REPL trades turned out.

REPL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered REPL in an article yet. Here's the latest on the wider market.

About Replimune Group

Replimune is a biotechnology company based in Woburn, Massachusetts, that develops oncolytic immunotherapies for cancer. These treatments use an engineered herpes simplex virus to kill tumor cells directly and to stimulate the immune system against the cancer. Its lead candidate, RP1, is being studied mainly in advanced melanoma and other skin cancers, with patients as the intended users. The company's products are still in clinical development and are not yet sold.

Headquarters
Woburn, MA